Serum Levels of Selected Hormones and Cognitive Functions in Schizophrenic Female Patients - Preliminary Results

Author(s):  
Krysta Krzysztof
QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Abeer I Abd Elmagid ◽  
Hala Abdel Al ◽  
Wessam El Sayed Saad ◽  
Seham Kamal Mohamed

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p < 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p > 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p > 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.


2021 ◽  
Vol 1-2 (33-34) ◽  
pp. 14-18
Author(s):  
V. Skybchyk ◽  
◽  
O. Pylypiv ◽  

Context. It is known that in addition to transient ischemic attacks and insults, hypertension is often the cause of asymptomatic brain damage, including cognitive impairment (CI). Most of these studies show a positive relationship between midlife hypertension and cognitive decline at the advanced age. CI significantly affect the quality of life of patients, reduce the ability to learn, acquire new knowledge and skills, force them to change their usual way of life and often stop or reduce professional activities. Objective. To analyze the condition of cognitive functions in patients with stage 1 and stage 2 hypertension of 2nd-3rd degrees, with moderate and high cardiovascular risk and evaluate their gender peculiarities. Materials and methods. The study included 90 patients with stage 1 and stage 2 hypertension. The average age of patients with hypertension was 49.66 ± 8.74 years old. The average course of the disease was 7.7 ± 3.9 years. The comparison group consisted of 46 healthy individuals with normal blood pressure levels and without hypertension in anamnesis (the average age - 45.88 ± 3.03 years old). Applied methods included general clinical, methods of neuropsychological testing (MMSE, GPCOG, W. Schulte test), standard general clinical and biochemical laboratory methods (blood lipid spectrum, blood glucose, creatinine with GFR, electrolytes), instrumental (12-lead ECG, ambulatory monitoring of blood pressure, echocardiography in B-, D-modes), and statistical methods. Results. Patients with hypertension scored significantly less on the MMSE scale (26.82 ± 1.41 scores vs. 28.89 ± 0.82 scores, p = 0.001) and GPCOG (6.63 ± 1.88 scores vs. 8.35 ± 0.71 scores, p = 0.001) compared with healthy individuals and spent more time on performing Walter Schulte test (46.51 ± 8.59 seconds vs. 36.69 ± 6.77 seconds, p = 0.001). Moderate CI were detected in 36 patients (40.00 %) among the examined hypertensive patients; it means that the total score of MMSE was 24-26 scores (the norm is 27-30 scores). The total score on the MMSE scale was 25.47 ± 0.88 in hypertensive patients with CI and was significantly lower than in hypertensive patients without CI (р = 0.001). Cognitive functions in patients with CI were characterized by poorer indices of memory, counting and executive functions. It should be noted that the revealed changes had more reliable manifestations in male hypertensive patients. In particular, the total score on the MMSE scale was 26.57 ± 1.37, while in female ones it was 27.19 ± 1.41 scores (p = 0.04). CI on the MMSE scale were diagnosed in 43.4 % (n = 23) of male patients and in 35.1 % (n = 13) of female patients. The total score was also higher on the GPCOG scale in female patients - 6.89 ± 1.85 scores vs. 6.45 ± 1.89 scores, p = 0.26. Instead, the time to complete the tasks according to the Walter Schulte tables was longer in male patients - 47.74 ± 8.85 seconds vs. 47.73 ± 7.99 seconds, p = 0.10, respectively. The parameters of counting functions were significantly lower (p = 0.01) in the group of male hypertensive patients compared with female ones. Besides, men had lower indicators of short-term memory and orientation, women reproduced worse verbal material, but the difference was statistically insignificant (p-value more than 0.05). The sum of scores on the MMSE scale conversely correlated with male gender (r = -0.22, p = 0.03). The risk of low values of MMSE indices in male patients with hypertension was 42.00 % higher than in female ones (OR = 1.42 ± 0.32, with 95% CІ [0.18-2.65]). Conclusions. Hypertension is a significant independent risk factor for developing new cases of cognitive impairment. In particular, among the patients with stage 1 and stage 2 hypertension of 2nd-3rd degrees, with moderate and high cardiovascular risk, moderate cognitive impairment was revealed in 36 patients (40,00 %), the revealed changes were more manifested in male hypertensive patients.


2018 ◽  
Vol 128 (9) ◽  
pp. 835-841 ◽  
Author(s):  
Ebtesam Mohamed Fahmy ◽  
Nervana Mohamed Elfayoumy ◽  
Ahmed Mohamed Abdelalim ◽  
Sahar Abdel-aaty Sharaf ◽  
Rania Shehata Ismail ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jing-Xu Chen ◽  
Jun-Hui Feng ◽  
Li-Gang Zhang ◽  
Yan Liu ◽  
Fu-De Yang ◽  
...  

Abstract Background Individuals with major depressive disorder (MDD) have a high suicide risk. Some evidence suggests that uric acid (UA) may be involved in the pathophysiology of MDD. The purpose of this study was to evaluate whether serum UA levels were associated with suicide risk in MDD patients. Methods One hundred four female patients with MDD (52 patients with suicide risk and 52 patients without suicide risk) and 52 healthy individuals were included in this study. The suicide risk was evaluated by Mini International Neuropsychiatric Interview (M.I.N.I.). Fasting serum levels of UA, as well as glucose, lipid and renal function indicators were measured. Results Serum UA levels in MDD patients with suicide risk (245.01 ± 55.44 μmol/L) were significantly lower than those in MDD patients without suicide risk (274.17 ± 72.65 μmol/L) (p = 0.017) and healthy controls (271.42 ± 55.25 μmol/L) (p = 0.030). There was no difference in serum UA levels between the MDD patients without suicide risk and healthy controls (p = 0.821). Binary logistic regression analysis revealed a significant relationship between suicide risk and decreased serum UA levels (OR = 0.989, p = 0.010) in MDD patients. Conclusion Decreased serum UA levels were associated with suicide risk in MDD patients. Purinergic system dysfunction may be involved in the neurobiological basis of suicide risk in these patients.


2003 ◽  
Vol 18 (3) ◽  
pp. 222-226 ◽  
Author(s):  
P.A. Iacovazzi ◽  
V. Guerra ◽  
S. Elba ◽  
F. Sportelli ◽  
O.G. Manghisi ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3715-3715 ◽  
Author(s):  
Michael Pfreundschuh ◽  
Niels Murawski ◽  
Samira Zeynalova ◽  
Viola Poeschel ◽  
Marcel Reiser ◽  
...  

Abstract Abstract 3715 Poster Board III-651 Background In the RICOVER-60 trial, where 1222 elderly (61-80 year-old) patients with untreated CD20-positive aggressive NHL were randomized to receive 6 or 8 cycles of CHOP-14 with or without 8 applications of rituximab, best results were obtained with 6xR-CHOP-14 plus 2 R in all subgroups of patients. To study the impact of sex on treatment outcome and pharmacokinetics, serum levels, patient characteristics and results were analyzed according to the patients' sex. Methods The results of 4 prospective DSHNHL trials (RICOVER-60: 1222 pts.; RICOVER-no-Rx: 164 pts; Pegfilgrastim trial: 103 pts., NHL-B2 trial: 241 pts.) in elderly patients with DLBCL who received CHOP-14 with or without rituximab were analyzed to compare the outcome of female and male patients. In addition, a pharmacokinetic study of rituximab was performed in 20 patients. Results Female patients in the RICOVER-60 trial presented with a significantly higher LDH and lower performance status compared to the male counterparts (elevated LDH: 53.7% vs. 45.7 %, p=0.005; ECOG >1: 17.3% vs. 11.8%, p=0.007). Nevertheless, female patients had a higher 3-year PFS (67.5% vs. 61.0%; p=0.062) and OS (74.2% vs. 68.4% p=0.086). The differences in outcome between female and male patients were largely due to a greater improvement of outcome achieved by the addition of rituximab in females: while the difference in 3-year PFS between female and male patients was 5.2% (p=0.448) in patients receiving CHOP-14 only, this increased to 7.6% (p=0.053) when rituximab was added. In a multivariate analysis adjusting for the IPI-relevant risk factors LDH, ECOG performance status, advanced stage and >1 extranodal involvement, the relative risk for progression in male compared to female patients was not significantly elevated after CHOP-14 only (1.1 p=0.348), but was significantly higher when rituximab was added (1.6 ; p=0.004). The different outcome of male and female patients was confirmed in the Pegfilgrastim trial, where the relative risk for males was 0.7 without and 3.3 (p=0.047) with rituximab in EFS. In the RICOVER-no-Rx study (164 pts) where all pts. received R-CHOP-14, the relative risk for males was 1.6, whereas in the NHL-B2 trial (241 pts.) where no rituximab was given, it was 1.3 for EFS. A pharmacokinetic study of the rituximab trough serum levels revealed that male patients had trough serum levels that were about one third lower in males than in females. Conclusion Rituximab improves outcome both in elderly female and male patients treated with CHOP-14; however, the positive effect of rituximab was more pronounced in female patients and renders male sex a significant risk factor under rituximab. In 4 prospective DSHNHL trials, the relative risk of male patients was consistently higher in males than in females when rituximab was given compared to treatment results obtained with CHOP-14 without rituximab. Our pharmacokinetic studies suggest that the increased relative risk of males might be due to lower rituximab serum levels which are probably due to the lower intrinsic clearance in female patients. These results together with the low toxicity of rituximab justify a trial with higher rituximab doses, which has recently been initiated by the DSHNHL. Supported by Deutsche Krebshilfe. Disclosures: Pfreundschuh: Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Travel Grants; Celgene: Consultancy; Lilly: Consultancy. Murawski:Roche: Travel grants. Schubert:Roche: Honoraria. Schmitz:Roche: Honoraria, Research Funding, travel grants.


1982 ◽  
Vol 12 (1) ◽  
pp. 191-192 ◽  
Author(s):  
R. J. Leeming ◽  
J. A. Blair ◽  
J. Walters

SynopsisSerum levels of 7, 8-dihydrobiopterin were significantly raised in female patients with depressive illness who were being treated with tricyclic antidepressants.


2009 ◽  
Vol 131 ◽  
pp. S143-S144
Author(s):  
Krzysztof Gutkowski ◽  
Teresa Kacperek-Hartleb ◽  
Maciej Kajor ◽  
Wlodzimierz Mazur ◽  
Grzegorz Boryczka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document